01:56 , Nov 20, 2015 |  BC Extra  |  Financial News

Shkreli investment gives KaloBios lifeline

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) gained $8.33 (402%) to $10.40 after it said Martin Shkreli and associated individuals acquired a majority stake in the company. KaloBios had said Nov. 13 that it would wind down operations...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

KaloBios cancer news

KaloBios will reduce headcount by about 17 (61%) to about 11 to focus resources on development of lenzilumab ( KB003 ) in chronic monomyelocytic leukemia (CMML) while it evaluates strategic alternatives, including a potential sale...
02:36 , Jan 7, 2015 |  BC Extra  |  Clinical News

KaloBios drops CF progam after Phase II miss

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The compound missed the primary...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors EPH receptor A3 (EPHA3) In vitro and mouse studies suggest EPHA3 antibodies could help treat solid tumors. In tissue samples from patients with...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

KB003: Development discontinued

KaloBios discontinued development of KB003 to treat severe asthma after top-line data from a double-blind, international Phase II trial in 160 patients with severe asthma inadequately controlled on corticosteroids showed that 400 mg IV KB003...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

KB004: Preliminary Phase I data

Preliminary data from 44 patients with relapsed or refractory hematologic malignancies in an open-label, dose-escalation, U.S. Phase I trial showed that IV KB004 on days 1, 8 and 15 of a 21-day cycle was well...
02:18 , Jan 30, 2014 |  BC Extra  |  Clinical News

KaloBios falls after dropping KB003 for asthma

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) fell $1.45 (31%) to $3.20 in early after-hours trading on Wednesday after the company announced after market close that it discontinued development of KB003 for severe asthma. The decision came after...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

KB004: Phase I started

KaloBios began an open-label, dose-escalation, U.S. Phase I trial to evaluate weekly 20, 70, 200 and 700 mg IV KB004 in a 21-day cycle for up to 17 cycles in up to 24 patients. Following...